60 Degrees Pharmaceuticals (NASDAQ:SXTP) Issues Quarterly Earnings Results, Misses Estimates By $0.52 EPS

60 Degrees Pharmaceuticals (NASDAQ:SXTP) announced its quarterly earnings data on Friday. The company reported ($1.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.52), FiscalAI reports. The company had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.44 million.

60 Degrees Pharmaceuticals Stock Performance

Shares of 60 Degrees Pharmaceuticals stock traded down $0.07 during trading on Friday, hitting $1.39. 21,402 shares of the stock were exchanged, compared to its average volume of 65,834. The stock’s fifty day moving average is $1.82 and its 200 day moving average is $3.00. The stock has a market cap of $3.67 million, a PE ratio of -0.10 and a beta of 2.69. 60 Degrees Pharmaceuticals has a 12 month low of $1.29 and a 12 month high of $14.68.

Analyst Ratings Changes

A number of research firms have recently issued reports on SXTP. Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a research report on Friday, March 27th. Wall Street Zen lowered 60 Degrees Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, April 12th. HC Wainwright increased their price target on 60 Degrees Pharmaceuticals from $6.00 to $24.00 and gave the stock a “buy” rating in a research report on Tuesday, January 27th. Finally, Ascendiant Capital Markets cut their price target on 60 Degrees Pharmaceuticals from $11.20 to $4.20 and set a “buy” rating on the stock in a report on Thursday, April 9th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, 60 Degrees Pharmaceuticals has a consensus rating of “Hold” and an average target price of $14.10.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.